Insulin aspart: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='PDB ID [[4gbc]]' scene='96/968809/Cv/1'> | <StructureSection load='' size='340' side='right' caption='PDB ID [[4gbc]]' scene='96/968809/Cv/1'> | ||
Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_aspart]. | Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [https://en.wikipedia.org/wiki/Insulin_aspart]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 15:04, 6 June 2023
Insulin aspart, sold under the brand name NovoLog and Fiasp, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. See also [1].
|
| ||||||||||